Your browser is no longer supported. Please, upgrade your browser.
Settings
SNSS Sunesis Pharmaceuticals, Inc. daily Stock Chart
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.94 Insider Own0.40% Shs Outstand20.40M Perf Week4.63%
Market Cap87.52M Forward P/E- EPS next Y-2.11 Insider Trans4.87% Shs Float20.40M Perf Month6.19%
Income-41.10M PEG- EPS next Q-0.43 Inst Own69.80% Short Float1.10% Perf Quarter5.15%
Sales2.50M P/S35.01 EPS this Y29.80% Inst Trans83.07% Short Ratio4.50 Perf Half Y442.97%
Book/sh-0.98 P/B- EPS next Y13.50% ROA-111.90% Target Price5.00 Perf Year479.57%
Cash/sh1.19 P/C3.62 EPS next 5Y- ROE- 52W Range0.44 - 5.00 Perf YTD18.51%
Dividend- P/FCF- EPS past 5Y12.70% ROI-210.20% 52W High-14.20% Beta1.71
Dividend %- Quick Ratio2.40 Sales past 5Y147.30% Gross Margin- 52W Low879.45% ATR0.12
Employees38 Current Ratio2.40 Sales Q/Q-14.30% Oper. Margin- RSI (14)71.21 Volatility4.17% 2.43%
OptionableYes Debt/Eq- EPS Q/Q-9.60% Profit Margin- Rel Volume1.25 Prev Close4.19
ShortableYes LT Debt/Eq- EarningsMar 09 BMO Payout- Avg Volume50.05K Price4.29
Recom2.30 SMA204.23% SMA509.36% SMA20064.68% Volume62,655 Change2.39%
Jul-29-16Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15Downgrade ROTH Capital Buy → Sell $5.50 → $1
Jul-24-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-15-15Reiterated ROTH Capital Buy $4 → $5.50
May-05-15Reiterated ROTH Capital Buy $4.30 → $4
Dec-15-14Upgrade ROTH Capital Neutral → Buy $2.30 → $4.30
Dec-09-14Reiterated ROTH Capital Neutral $1.30 → $2.30
Oct-07-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
Oct-07-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
Jun-12-14Initiated UBS Buy $14
Sep-11-12Reiterated Cantor Fitzgerald Buy $6 → $8
May-29-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
Apr-13-12Initiated Cantor Fitzgerald Buy $6
Mar-06-12Initiated Canaccord Genuity Buy $4
Oct-11-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
Sep-29-11Initiated MLV Capital Buy $3.50
Feb-24-17 03:25PM  Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
Feb-23-17 09:58AM  Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
Feb-22-17 05:08PM  Pfizer's Leukemia Candidate Gets Priority Review in U.S.
Feb-20-17 09:06AM  ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
Feb-17-17 02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
09:27AM  Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
Feb-16-17 04:19PM  Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
Feb-15-17 02:36PM  Prothena (PRTA) Reports Wider-than-Expected Loss in Q4
10:08AM  AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
Feb-10-17 02:15PM  Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss
Feb-08-17 09:30AM  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Feb-07-17 03:26PM  5 Great Biotech Stocks to Buy Now
10:56AM  Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
Feb-06-17 07:00AM  Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Feb-02-17 09:49AM  Novartis (NVS) Votubia Gets EU Approval for Label Expansion
Jan-31-17 05:40PM  Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval
10:46AM  Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues
Jan-30-17 05:27PM  Novo Nordisk Inks Diabetes Deal with University of Oxford
04:19PM  Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
10:20AM  Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
08:00AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
Jan-27-17 05:36PM  AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA
05:10PM  Immunogen Doses First Patient in Ovarian Cancer Drug Study
09:05AM  Endo (ENDP) Restructures its Branded Pharmaceutical Unit
08:53AM  J&J to Acquire Actelion for $30B: Is It a Strategic Fit?
Jan-26-17 03:29PM  Celgene (CELG) Misses on Earnings & Revenues, Keeps View
Jan-25-17 05:30PM  Roche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA
08:45AM  Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon
Jan-24-17 04:06PM  Sunesis Offers Updates on SNS-062 and Qinprezo Programs
09:50AM  Endo (ENDP) Settles Disputes with Federal Trade Commission
09:21AM  Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission
08:20AM  Marinus Releases Positive Preliminary Data from CDKL5 Study
Jan-23-17 10:20AM  Minerva Presents Additional Data from Schizophrenia Drug
07:00AM  Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs GlobeNewswire
Jan-20-17 08:39AM  Aduro (ADRO) Inks License Agreement with Stanford University
08:38AM  Synergy (SGYP) Trulance Wins FDA Approval for Constipation
Jan-18-17 08:28AM  Kura Oncology Starts Dosing Patients in Phase II CMML Study
Dec-15-16 07:57PM  How MEI Pharma Inc (MEIP) Stacks Up Against Its Peers at Insider Monkey
Dec-05-16 05:45PM  Sunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting GlobeNewswire
07:00AM  Sunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting GlobeNewswire
Nov-10-16 01:04PM  SUNESIS PHARMACEUTICALS INC Financials
Nov-03-16 11:10AM  Sunesis reports 3Q loss
11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
09:25AM  Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting GlobeNewswire
07:07AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:00AM  Sunesis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Nov-02-16 07:59AM  Sunesis Pharmaceuticals Inc (SNSS): Cormorant Asset Management Reports New 5.14% Stake at Insider Monkey
Oct-27-16 07:00AM  Sunesis to Host Conference Call on November 3rd to Discuss Third Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Oct-24-16 04:05PM  Sunesis Announces Closing of Public Offerings and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-19-16 04:11PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to
09:07AM  Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More at Insider Monkey
09:02AM  Sunesis Announces Pricing of $25 Million Offering of Securities GlobeNewswire
Oct-18-16 04:01PM  Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock GlobeNewswire
07:00AM  Sunesis Pharmaceuticals to Present at the Dawson James Securities 2nd Annual Small Cap Growth Stock Conference GlobeNewswire
Oct-14-16 10:03AM  Sunesis Submits Response to Questions on Leukemia Drug
Oct-13-16 04:05PM  Sunesis Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin GlobeNewswire
Sep-27-16 01:11PM  What it Costs Apple to Make an iPhone 7: $219 Parts, $5 Labor at Investopedia
Sep-26-16 04:13PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Sep-12-16 05:15PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Sunesis Pharmaceuticals, Inc. Preliminary Results From the Oral Non-Covalent BTK-inhibitor SNS-062 Call scheduled for 8:00 am ET today
06:00AM  Sunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 GlobeNewswire
Sep-09-16 11:24AM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : September 9, 2016 +8.99%
Sep-07-16 05:03PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina -10.18%
02:00PM  Sunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split GlobeNewswire
Sep-01-16 07:00AM  Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematologys 2nd International Conference o GlobeNewswire
Aug-31-16 07:00AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
Aug-25-16 07:00AM  Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin GlobeNewswire +12.66%
Aug-18-16 06:53PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : August 18, 2016 +6.49%
08:15AM  Sunesis Pharmaceuticals (SNSS) Jumps: Stock Rises 23.1%
Aug-04-16 03:17PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : August 4, 2016
Aug-03-16 01:48PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
Aug-01-16 12:36PM  Edited Transcript of SNSS earnings conference call or presentation 29-Jul-16 3:00pm GMT +7.56%
Jul-29-16 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today +28.44%
09:18AM  Sunesis reports 2Q loss
08:15AM  Sunesis Pharma upgraded by Wells Fargo
07:32AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:07AM  Q2 2016 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Jul-21-16 07:00AM  Sunesis to Host Conference Call on July 29th to Discuss Second Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Jul-05-16 07:00AM  Sunesis Pharmaceuticals to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference GlobeNewswire
Jun-21-16 08:45AM  Sunesis Pharmaceuticals (SNSS) in Focus: Stock Gains 8.7%
Jun-17-16 11:00AM  7 Biotech Stocks that are Buys Right Now
Jun-13-16 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting GlobeNewswire
Jun-09-16 09:42AM  Most Popular Healthcare Penny Stocks Among Hedge Funds at Insider Monkey -5.87%
Jun-08-16 04:14PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-06-16 05:43PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : June 6, 2016 -5.02%
09:12AM  Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting GlobeNewswire
Jun-01-16 07:00AM  Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development GlobeNewswire
May-27-16 06:08AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
May-25-16 09:00AM  Sunesis Pharmaceuticals Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June GlobeNewswire
May-19-16 07:58PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 19, 2016
07:28AM  Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association GlobeNewswire
May-18-16 01:56PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2016 By the Numbers
07:00AM  Sunesis to Present at the 2016 UBS Global Healthcare Conference GlobeNewswire
May-11-16 04:14PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -5.48%
May-09-16 04:40PM  SUNESIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
May-05-16 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
09:40AM  Sunesis reports 1Q loss
07:07AM  Q1 2016 Sunesis Pharmaceuticals Inc Earnings Release - Time Not Supplied
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton's tyrosine kinase; The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Geoffrey M.DirectorDec 09Buy3.905942,31865,745Dec 12 06:43 PM
Parker Geoffrey M.DirectorDec 08Buy3.873,14612,15965,151Dec 12 06:43 PM
Parker Geoffrey M.DirectorMay 26Buy0.479,5004,45562,005May 27 05:26 PM
Parker Geoffrey M.DirectorMay 25Buy0.4922,50510,93352,505May 26 05:04 PM
Parker Geoffrey M.DirectorMay 24Buy0.4630,00013,88130,000May 26 05:04 PM